Access to exercise ‐based rehabilitation across Europe for patients with heart failure: where evidence‐based practice is hampered by lacking resources
European Journal of Heart Failure, EarlyView. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - July 4, 2019 Category: Cardiology Authors: Dominique Hansen Tags: Editorial Comment Source Type: research

In ‐hospital red blood cell distribution width change in patients with heart failure
European Journal of Heart Failure, EarlyView. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - July 4, 2019 Category: Cardiology Authors: Andrew Xanthopoulos, Michail Papamichalis, Alex Zajichek, Alex Milinovich, Michael W. Kattan, John Skoularigis, Randall C. Starling, Filippos Triposkiadis Tags: Research Letter Source Type: research

Access to exercise ‐based rehabilitation across Europe for patients with heart failure: where evidence‐based practice is hampered by lacking resources
European Journal of Heart Failure, EarlyView. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - July 4, 2019 Category: Cardiology Authors: Dominique Hansen Tags: Editorial Comment Source Type: research

In ‐hospital red blood cell distribution width change in patients with heart failure
European Journal of Heart Failure, EarlyView. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - July 4, 2019 Category: Cardiology Authors: Andrew Xanthopoulos, Michail Papamichalis, Alex Zajichek, Alex Milinovich, Michael W. Kattan, John Skoularigis, Randall C. Starling, Filippos Triposkiadis Tags: Research Letter Source Type: research

Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction
We examined the association between diabetes/diabetes treatments and the risk of the primary composite of cardiovascular death or HF hospitalization, as well as other outcomes in adjusted analyses in CHARM ‐Preserved (left ventricular ejection fraction ≥ 45%), I‐Preserve and TOPCAT (Americas) pooled. Of 8466 patients, 2653 (31%) had diabetes, including 979 (37%) receiving insulin. Patients receiving insulin were younger, had a higher body mass index, prevalence of ischaemic aetiology, N‐term inal pro‐B‐type natriuretic peptide and use of diuretics, worse New York Heart Association class and signs and sy...
Source: European Journal of Heart Failure - July 4, 2019 Category: Cardiology Authors: Li Shen, Rasmus R ørth, Deborah Cosmi, Søren Lund Kristensen, Mark C. Petrie, Franco Cosmi, Roberto Latini, Lars Køber, Inder S. Anand, Peter E. Carson, Christopher B. Granger, Michel Komajda, Robert S. McKelvie, Scott D. Solomon, Lidia S Tags: Research Article Source Type: research

Retinal microvascular dysfunction in patients with coronary artery disease with and without heart failure: a continuum?
AbstractAimsDynamic retinal vessel analysis is a novel, non ‐invasive method to assess microvascular function. The primary aim of this study was to investigate whether retinal microcirculation is impaired in patients with stable coronary artery disease (CAD) compared to patients with heart failure due to CAD (ischaemic heart failure, IHF).Methods and resultsA total of 150 adults were enrolled to prospectively assess micro ‐ and macrovasculature. The pre‐defined primary outcome was flicker‐induced arterial dilatation (FIDa) in patients with CAD [n = 40; median age 63 years, interquartile range (IQR) 53&n...
Source: European Journal of Heart Failure - July 4, 2019 Category: Cardiology Authors: Jens Barthelmes, Matthias P. N ägele, Silviya Cantatore, Etibar Novruzov, Valeria Ludovici, Arnold von Eckardstein, Michelle Frank, Frank Ruschitzka, Isabella Sudano, Andreas J. Flammer Tags: Research Article Source Type: research

Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction
We examined the association between diabetes/diabetes treatments and the risk of the primary composite of cardiovascular death or HF hospitalization, as well as other outcomes in adjusted analyses in CHARM ‐Preserved (left ventricular ejection fraction ≥ 45%), I‐Preserve and TOPCAT (Americas) pooled. Of 8466 patients, 2653 (31%) had diabetes, including 979 (37%) receiving insulin. Patients receiving insulin were younger, had a higher body mass index, prevalence of ischaemic aetiology, N‐term inal pro‐B‐type natriuretic peptide and use of diuretics, worse New York Heart Association class and signs and sy...
Source: European Journal of Heart Failure - July 4, 2019 Category: Cardiology Authors: Li Shen, Rasmus R ørth, Deborah Cosmi, Søren Lund Kristensen, Mark C. Petrie, Franco Cosmi, Roberto Latini, Lars Køber, Inder S. Anand, Peter E. Carson, Christopher B. Granger, Michel Komajda, Robert S. McKelvie, Scott D. Solomon, Lidia S Tags: Research Article Source Type: research

Retinal microvascular dysfunction in patients with coronary artery disease with and without heart failure: a continuum?
AbstractAimsDynamic retinal vessel analysis is a novel, non ‐invasive method to assess microvascular function. The primary aim of this study was to investigate whether retinal microcirculation is impaired in patients with stable coronary artery disease (CAD) compared to patients with heart failure due to CAD (ischaemic heart failure, IHF).Methods and resultsA total of 150 adults were enrolled to prospectively assess micro ‐ and macrovasculature. The pre‐defined primary outcome was flicker‐induced arterial dilatation (FIDa) in patients with CAD [n = 40; median age 63 years, interquartile range (IQR) 53&n...
Source: European Journal of Heart Failure - July 4, 2019 Category: Cardiology Authors: Jens Barthelmes, Matthias P. N ägele, Silviya Cantatore, Etibar Novruzov, Valeria Ludovici, Arnold von Eckardstein, Michelle Frank, Frank Ruschitzka, Isabella Sudano, Andreas J. Flammer Tags: Research Article Source Type: research

Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy
Peripartum cardiomyopathy (PPCM) is a potentially life ‐threatening condition typically presenting as heart failure with reduced ejection fraction (HFrEF) in the last month of pregnancy or in the months following delivery in women without another known cause of heart failure. This updated position statement summarizes the knowledge about pathophysiolo gical mechanisms, risk factors, clinical presentation, diagnosis and management of PPCM. As shortness of breath, fatigue and leg oedema are common in the peripartum period, a high index of suspicion is required to not miss the diagnosis. Measurement of natriuretic peptides,...
Source: European Journal of Heart Failure - June 27, 2019 Category: Cardiology Authors: Johann Bauersachs, Tobias K önig, Peter Meer, Mark C. Petrie, Denise Hilfiker‐Kleiner, Amam Mbakwem, Righab Hamdan, Alice M. Jackson, Paul Forsyth, Rudolf A. Boer, Christian Mueller, Alexander R. Lyon, Lars H. Lund, Massimo F. Piepoli, St Tags: Position Paper Source Type: research

Issue Information
European Journal of Heart Failure, Volume 21, Issue 6, Page i-vi, June 2019. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - June 20, 2019 Category: Cardiology Tags: ISSUE INFORMATION Source Type: research

June 2019 at a glance: from genetics to haemodynamics, biomarkers and imaging for the prediction of outcomes
European Journal of Heart Failure, Volume 21, Issue 6, Page 697-698, June 2019. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - June 20, 2019 Category: Cardiology Authors: Marco Metra Tags: Introduction Source Type: research

Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations
Natriuretic peptide [NP; B ‐type NP (BNP), N‐terminal proBNP (NT‐proBNP), and midregional proANP (MR‐proANP)] concentrations are quantitative plasma biomarkers for the presence and severity of haemodynamic cardiac stress and heart failure (HF). End‐diastolic wall stress, intracardiac filling pressures, and intracard iac volumes seem to be the dominant triggers. This paper details the most important indications for NPs and highlights 11 key principles underlying their clinical use shown below. NPs should always be used in conjunction with all other clinical information. NPs are reasonable surrogates for intracar d...
Source: European Journal of Heart Failure - June 20, 2019 Category: Cardiology Authors: Christian Mueller, Kenneth McDonald, Rudolf A. de Boer, Alan Maisel, John G.F. Cleland, Nikola Kozhuharov, Andrew J.S. Coats, Marco Metra, Alexandre Mebazaa, Frank Ruschitzka, Mitja Lainscak, Gerasimos Filippatos, Petar M. Seferovic, Wouter C Tags: Position Paper Source Type: research

Issue Information
European Journal of Heart Failure, Volume 21, Issue 6, Page i-vi, June 2019. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - June 20, 2019 Category: Cardiology Tags: ISSUE INFORMATION Source Type: research

June 2019 at a glance: from genetics to haemodynamics, biomarkers and imaging for the prediction of outcomes
European Journal of Heart Failure, Volume 21, Issue 6, Page 697-698, June 2019. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - June 20, 2019 Category: Cardiology Authors: Marco Metra Tags: Introduction Source Type: research

Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations
Natriuretic peptide [NP; B ‐type NP (BNP), N‐terminal proBNP (NT‐proBNP), and midregional proANP (MR‐proANP)] concentrations are quantitative plasma biomarkers for the presence and severity of haemodynamic cardiac stress and heart failure (HF). End‐diastolic wall stress, intracardiac filling pressures, and intracard iac volumes seem to be the dominant triggers. This paper details the most important indications for NPs and highlights 11 key principles underlying their clinical use shown below. NPs should always be used in conjunction with all other clinical information. NPs are reasonable surrogates for intracar d...
Source: European Journal of Heart Failure - June 20, 2019 Category: Cardiology Authors: Christian Mueller, Kenneth McDonald, Rudolf A. de Boer, Alan Maisel, John G.F. Cleland, Nikola Kozhuharov, Andrew J.S. Coats, Marco Metra, Alexandre Mebazaa, Frank Ruschitzka, Mitja Lainscak, Gerasimos Filippatos, Petar M. Seferovic, Wouter C Tags: Position Paper Source Type: research

In ‐hospital initiation of sacubitril/valsartan in acute decompensated heart failure: being in the right place at the right time
European Journal of Heart Failure, EarlyView. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - June 19, 2019 Category: Cardiology Authors: Andrew P. Ambrosy, Adam D. DeVore, Eric J. Velazquez Tags: Editorial Comment Source Type: research

Rationale and design of the EMPERIAL ‐Preserved and EMPERIAL‐Reduced trials of empagliflozin in patients with chronic heart failure
ConclusionThe EMPERIAL ‐Preserved and EMPERIAL‐Reduced trials will determine the effects of empagliflozin on exercise capacity and patient‐reported outcomes in patients with HFpEF and HFrEF, respectively, and provide insight into the potential of empagliflozin in the treatment of patients with HF.Clinical Trial Registration:ClinicalTrials.gov ID: NCT03448406 (EMPERIAL ‐Preserved), NCT03448419 (EMPERIAL‐Reduced). (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - June 19, 2019 Category: Cardiology Authors: William T. Abraham, Piotr Ponikowski, Martina Brueckmann, Cordula Zeller, Hemani Macesic, Barbara Peil, Mich èle Brun, Anastasia Ustyugova, Waheed Jamal, Afshin Salsali, JoAnn Lindenfeld, Stefan D. Anker, on behalf of the EMPERIAL Investigato Tags: Study Design Source Type: research

Expert consensus document: Reporting checklist for quantification of pulmonary congestion by lung ultrasound in heart failure
AbstractLung ultrasound is a useful tool for the assessment of patients with both acute and chronic heart failure, but the use of different image acquisition methods, inconsistent reporting of the technique employed and variable quantification of ‘B‐lines,’ have all made it difficult to compare published reports. We therefore need to ensure that future studies utilizing lung ultrasound in the assessment of heart failure adopt a standardized approach to reporting the quantification of pulmonary congestion. Strategies to improve patient care by use of lung ultrasound in the assessment of heart failure have been...
Source: European Journal of Heart Failure - June 19, 2019 Category: Cardiology Authors: Elke Platz, Pardeep S. Jhund, Nicolas Girerd, Emanuele Pivetta, John J.V. McMurray, W. Frank Peacock, Josep Masip, Francisco Javier Martin ‐Sanchez, Òscar Miró, Susanna Price, Louise Cullen, Alan S. Maisel, Christiaan Vrints, Martin R. Co Tags: Consensus Document Source Type: research

In ‐hospital initiation of sacubitril/valsartan in acute decompensated heart failure: being in the right place at the right time
European Journal of Heart Failure, EarlyView. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - June 19, 2019 Category: Cardiology Authors: Andrew P. Ambrosy, Adam D. DeVore, Eric J. Velazquez Tags: Editorial Comment Source Type: research

Rationale and design of the EMPERIAL ‐Preserved and EMPERIAL‐Reduced trials of empagliflozin in patients with chronic heart failure
ConclusionThe EMPERIAL ‐Preserved and EMPERIAL‐Reduced trials will determine the effects of empagliflozin on exercise capacity and patient‐reported outcomes in patients with HFpEF and HFrEF, respectively, and provide insight into the potential of empagliflozin in the treatment of patients with HF.Clinical Trial Registration:ClinicalTrials.gov ID: NCT03448406 (EMPERIAL ‐Preserved), NCT03448419 (EMPERIAL‐Reduced). (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - June 19, 2019 Category: Cardiology Authors: William T. Abraham, Piotr Ponikowski, Martina Brueckmann, Cordula Zeller, Hemani Macesic, Barbara Peil, Mich èle Brun, Anastasia Ustyugova, Waheed Jamal, Afshin Salsali, JoAnn Lindenfeld, Stefan D. Anker, on behalf of the EMPERIAL Investigato Tags: Study Design Source Type: research

Expert consensus document: Reporting checklist for quantification of pulmonary congestion by lung ultrasound in heart failure
AbstractLung ultrasound is a useful tool for the assessment of patients with both acute and chronic heart failure, but the use of different image acquisition methods, inconsistent reporting of the technique employed and variable quantification of ‘B‐lines,’ have all made it difficult to compare published reports. We therefore need to ensure that future studies utilizing lung ultrasound in the assessment of heart failure adopt a standardized approach to reporting the quantification of pulmonary congestion. Strategies to improve patient care by use of lung ultrasound in the assessment of heart failure have been...
Source: European Journal of Heart Failure - June 19, 2019 Category: Cardiology Authors: Elke Platz, Pardeep S. Jhund, Nicolas Girerd, Emanuele Pivetta, John J.V. McMurray, W. Frank Peacock, Josep Masip, Francisco Javier Martin ‐Sanchez, Òscar Miró, Susanna Price, Louise Cullen, Alan S. Maisel, Christiaan Vrints, Martin R. Co Tags: Consensus Document Source Type: research

Sacubitril/valsartan eligibility and outcomes in the ESC ‐EORP‐HFA Heart Failure Long‐Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM‐HF trial, ESC guidelines, and real world
ConclusionsAmong outpatients with HFrEF in the ESC ‐EORP‐HFA HF‐LT Registry, 84% met label criteria, while only 12% and 28% met PARADIGM‐HF and guideline criteria for LCZ696 if requiring ≥ 20 mg and ≥ 10 mg enalapril, respectively. Registry patients eligible for LCZ696 had greater heart failure hospitalization but lower mortality rates than the PARADIGM‐HF enalapril group. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - June 18, 2019 Category: Cardiology Authors: Chris J. Kapelios, Mitja Lainscak, Gianluigi Savarese, C écile Laroche, Petar Seferovic, Frank Ruschitzka, Andrew Coats, Stefan D. Anker, Maria G. Crespo‐Leiro, Gerasimos Filippatos, Massimo F. Piepoli, Giuseppe Rosano, Luisa Zanolla, Carl Tags: Research Article Source Type: research

Definition and treatment of arrhythmogenic cardiomyopathy: an updated expert panel report
AbstractIt is 35  years since the first description of arrhythmogenic right ventricular cardiomyopathy (ARVC) and more than 20 years since the first reports establishing desmosomal gene mutations as a major cause of the disease. Early advances in the understanding of the clinical, pathological and genetic archit ecture of ARVC resulted in consensus diagnostic criteria, which proved to be sensitive but not entirely specific for the disease. In more recent years, clinical and genetic data from families and the recognition of a much broader spectrum of structural disorders affecting both ventricles and associa t...
Source: European Journal of Heart Failure - June 18, 2019 Category: Cardiology Authors: Perry M. Elliott, Aris Anastasakis, Angeliki Asimaki, Cristina Basso, Barbara Bauce, Matthew A. Brooke, Hugh Calkins, Domenico Corrado, Firat Duru, Kathleen J. Green, Daniel P. Judge, David Kelsell, Pier D. Lambiase, William J. McKenna, Kall Tags: Consensus Document Source Type: research

Sacubitril/valsartan eligibility and outcomes in the ESC ‐EORP‐HFA Heart Failure Long‐Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM‐HF trial, ESC guidelines, and real world
ConclusionsAmong outpatients with HFrEF in the ESC ‐EORP‐HFA HF‐LT Registry, 84% met label criteria, while only 12% and 28% met PARADIGM‐HF and guideline criteria for LCZ696 if requiring ≥ 20 mg and ≥ 10 mg enalapril, respectively. Registry patients eligible for LCZ696 had greater heart failure hospitalization but lower mortality rates than the PARADIGM‐HF enalapril group. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - June 18, 2019 Category: Cardiology Authors: Chris J. Kapelios, Mitja Lainscak, Gianluigi Savarese, C écile Laroche, Petar Seferovic, Frank Ruschitzka, Andrew Coats, Stefan D. Anker, Maria G. Crespo‐Leiro, Gerasimos Filippatos, Massimo F. Piepoli, Giuseppe Rosano, Luisa Zanolla, Carl Tags: Research Article Source Type: research

Definition and treatment of arrhythmogenic cardiomyopathy: an updated expert panel report
AbstractIt is 35  years since the first description of arrhythmogenic right ventricular cardiomyopathy (ARVC) and more than 20 years since the first reports establishing desmosomal gene mutations as a major cause of the disease. Early advances in the understanding of the clinical, pathological and genetic archit ecture of ARVC resulted in consensus diagnostic criteria, which proved to be sensitive but not entirely specific for the disease. In more recent years, clinical and genetic data from families and the recognition of a much broader spectrum of structural disorders affecting both ventricles and associa t...
Source: European Journal of Heart Failure - June 18, 2019 Category: Cardiology Authors: Perry M. Elliott, Aris Anastasakis, Angeliki Asimaki, Cristina Basso, Barbara Bauce, Matthew A. Brooke, Hugh Calkins, Domenico Corrado, Firat Duru, Kathleen J. Green, Daniel P. Judge, David Kelsell, Pier D. Lambiase, William J. McKenna, Kall Tags: Consensus Document Source Type: research

Mid ‐regional pro‐atrial natriuretic peptide for the early detection of non‐acute heart failure
ConclusionMR ‐proANP provides added diagnostic value in suspected non‐acute HF, similar to NT‐proBNP. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - June 17, 2019 Category: Cardiology Authors: Aisha Gohar, Frans H. Rutten, Hester Ruijter, Johannes C. Kelder, Stephan Haehling, Stefan D. Anker, Martin M öckel, Arno W. Hoes Tags: Research Article Source Type: research

Myocardial substrate changes in advanced ischaemic and advanced dilated human heart failure
European Journal of Heart Failure, EarlyView. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - June 11, 2019 Category: Cardiology Authors: Jacob Cao, Yen Chin Koay, Lake ‐Ee Quek, Benjamin Parker, Sean Lal, John F. O'Sullivan Tags: Research Letter Source Type: research

Rationale and design for the development of a novel nitroxyl donor in patients with acute heart failure
Hospitalisation for acute heart failure remains a major public health problem with high prevalence, morbidity, mortality, and cost. Prior attempts to develop new therapies for this condition have not been successful. Nitroxyl (HNO) plays a unique role in cardiovascular physiology by direct post ‐translational modification of thiol residues on target proteins, specifically SERCA2a, phospholamban, the ryanodine receptor and myofilament proteins in cardiomyocytes. In animal models, these biological effects lead to vasodilatation, increased inotropy and lusitropy, but without tachyphylaxis, pro‐arrhythmia or evidence of in...
Source: European Journal of Heart Failure - June 6, 2019 Category: Cardiology Authors: G. Michael Felker, Maria Borentain, John G. Cleland, Mary M. DeSouza, Paul D. Kessler, Christopher M. O'Connor, Dietmar Seiffert, John R. Teerlink, Adriaan A. Voors, John J.V. McMurray Tags: Study Design Source Type: research

Major reduction in the risk of sudden cardiac death in patients with chronic heart failure with the use of drug and device combinations that favourably affect left ventricular structure
European Journal of Heart Failure, EarlyView. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - May 29, 2019 Category: Cardiology Authors: Milton Packer Tags: Viewpoint Source Type: research

Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study
ConclusionsInitiation of sacubitril/valsartan in a wide range of heart failure with reduced ejection fraction patients stabilised after an AHF event, either in hospital or shortly after discharge, is feasible with about half of the patients achieving target dose within 10  weeks.Clinical Trial Registration:ClinicalTrials.gov ID: NCT02661217 (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - May 27, 2019 Category: Cardiology Authors: Rolf Wachter, Michele Senni, Jan Belohlavek, Ewa Straburzynska ‐Migaj, Klaus K. Witte, Zhanna Kobalava, Candida Fonseca, Eva Goncalvesova, Yuksel Cavusoglu, Alberto Fernandez, Said Chaaban, Ellen Bøhmer, Anne‐Catherine Pouleur, Christian Tags: Research Article Source Type: research

Sacubitril/valsartan eligibility and outcomes in the ESC HFA EORP Heart Failure Long ‐Term Registry: bridging between EMA/FDA label, the PARADIGM‐HF trial, ESC Guidelines, and real‐world
ConclusionsAmong outpatients with HFrEF in the ESC ‐HFA‐HF‐LT registry, 84% met label criteria, while only 12% and 28% met PARADIGM‐HF and Guidelines criteria for LCZ696 if requiring ≥20 mg and ≥10 mg enalapril, respectively. Registry patients eligible for LCZ696 had greater HF hospitalization but lower mortality rates then the PARADIGM‐ HF enalapril group. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - May 27, 2019 Category: Cardiology Authors: Chris J. Kapelios, Mitja Lainscak, Gianluigi Savarese, C écile Laroche, Petar Seferovic, Frank Ruschitzka, Andrew Coats, Stefan D. Anker, Maria G. Crespo‐Leiro, Gerasimos Filippatos, Massimo F. Piepoli, Giuseppe Rosano, Luisa Zanolla, Carl Tags: Research Article Source Type: research

Initiation of sacubitril/valsartan in haemodynamically stabilised heart failure patients in hospital or early after discharge: primary results of the randomised TRANSITION study
ConclusionsInitiation of sacubitril/valsartan in a wide range of heart failure with reduced ejection fraction patients stabilised after an AHF event, either in hospital or shortly after discharge, is feasible with about half of the patients achieving target dose within 10  weeks.Clinical Trial Registration:ClinicalTrials.gov ID: NCT02661217 (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - May 27, 2019 Category: Cardiology Authors: Rolf Wachter, Michele Senni, Jan Belohlavek, Ewa Straburzynska ‐Migaj, Klaus K. Witte, Zhanna Kobalava, Candida Fonseca, Eva Goncalvesova, Yuksel Cavusoglu, Alberto Fernandez, Said Chaaban, Ellen Bøhmer, Anne‐Catherine Pouleur, Christian Tags: Research Article Source Type: research

Sacubitril/valsartan eligibility and outcomes in the ESC HFA EORP Heart Failure Long ‐Term Registry: bridging between EMA/FDA label, the PARADIGM‐HF trial, ESC Guidelines, and real‐world
ConclusionsAmong outpatients with HFrEF in the ESC ‐HFA‐HF‐LT registry, 84% met label criteria, while only 12% and 28% met PARADIGM‐HF and Guidelines criteria for LCZ696 if requiring ≥20 mg and ≥10 mg enalapril, respectively. Registry patients eligible for LCZ696 had greater HF hospitalization but lower mortality rates then the PARADIGM‐ HF enalapril group. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - May 27, 2019 Category: Cardiology Authors: Chris J. Kapelios, Mitja Lainscak, Gianluigi Savarese, C écile Laroche, Petar Seferovic, Frank Ruschitzka, Andrew Coats, Stefan D. Anker, Maria G. Crespo‐Leiro, Gerasimos Filippatos, Massimo F. Piepoli, Giuseppe Rosano, Luisa Zanolla, Carl Tags: Research Article Source Type: research

Issue Information
European Journal of Heart Failure, Volume 21, Issue S1, Page 1-2, May 2019. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - May 26, 2019 Category: Cardiology Tags: Issue Information Source Type: research

Author index
European Journal of Heart Failure, Volume 21, Issue S1, Page 593-641, May 2019. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - May 26, 2019 Category: Cardiology Tags: Author index Source Type: research

Abstracts Programme
European Journal of Heart Failure, Volume 21, Issue S1, Page 5-592, May 2019. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - May 26, 2019 Category: Cardiology Tags: Abstracts Programme Source Type: research

Heart Failure 2019 Abstract Reviewers
European Journal of Heart Failure, Volume 21, Issue S1, Page 3-4, May 2019. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - May 26, 2019 Category: Cardiology Tags: Heart Failure 2019 Abstract Reviewers Source Type: research

Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of The Heart Failure Association of the European Society of Cardiology
ABSTRACTThe ESC has published a series of guidelines on heart failure (HF) over the last 25 years, most recently in 2016. Given the amount of new information that has become available since then, the HFA of the ESC recognized the need to review and summarise recent developments in a consensus document. Here we report from the HFA workshop that was held in January 2019 in Frankfurt. This expert consensus report is neither a guideline update nor a position statement, but rather a summary and consensus view in the form of consensus recommendations. The report describes how these guidance statements are supported by evidence, ...
Source: European Journal of Heart Failure - May 26, 2019 Category: Cardiology Authors: Petar M. Seferovic, Piotr Ponikowski, Stefan D. Anker, Johann Bauersachs, Ovidiu Chioncel, John G. F. Cleland, Rudolf A. de Boer, Heinz Drexel, Tuvia Ben Gal, Loreena Hill, Tiny Jaarsma, Ewa A. Jankowska, Markus S. Anker, Mitja Lainscak, Bas Tags: Research Article Source Type: research

Issue Information
European Journal of Heart Failure, Volume 21, Issue S1, Page 1-2, May 2019. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - May 26, 2019 Category: Cardiology Tags: Issue Information Source Type: research

Author index
European Journal of Heart Failure, Volume 21, Issue S1, Page 593-641, May 2019. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - May 26, 2019 Category: Cardiology Tags: Author index Source Type: research

Abstracts Programme
European Journal of Heart Failure, Volume 21, Issue S1, Page 5-592, May 2019. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - May 26, 2019 Category: Cardiology Tags: Abstracts Programme Source Type: research

Heart Failure 2019 Abstract Reviewers
European Journal of Heart Failure, Volume 21, Issue S1, Page 3-4, May 2019. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - May 26, 2019 Category: Cardiology Tags: Heart Failure 2019 Abstract Reviewers Source Type: research

Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of The Heart Failure Association of the European Society of Cardiology
ABSTRACTThe ESC has published a series of guidelines on heart failure (HF) over the last 25 years, most recently in 2016. Given the amount of new information that has become available since then, the HFA of the ESC recognized the need to review and summarise recent developments in a consensus document. Here we report from the HFA workshop that was held in January 2019 in Frankfurt. This expert consensus report is neither a guideline update nor a position statement, but rather a summary and consensus view in the form of consensus recommendations. The report describes how these guidance statements are supported by evidence, ...
Source: European Journal of Heart Failure - May 26, 2019 Category: Cardiology Authors: Petar M. Seferovic, Piotr Ponikowski, Stefan D. Anker, Johann Bauersachs, Ovidiu Chioncel, John G. F. Cleland, Rudolf A. de Boer, Heinz Drexel, Tuvia Ben Gal, Loreena Hill, Tiny Jaarsma, Ewa A. Jankowska, Markus S. Anker, Mitja Lainscak, Bas Tags: Research Article Source Type: research

Pharmacy ‐based interdisciplinary intervention for patients with chronic heart failure: results of the PHARM‐CHF randomized controlled trial
ConclusionPharmacy care safely improved adherence to heart failure medications and quality of life. (Source: European Journal of Heart Failure)
Source: European Journal of Heart Failure - May 25, 2019 Category: Cardiology Authors: Martin Schulz, Nina Griese ‐Mammen, Stefan D. Anker, Friedrich Koehler, Peter Ihle, Christian Ruckes, Pia M. Schumacher, Dietmar Trenk, Michael Böhm, Ulrich Laufs, for the PHARM‐CHF investigators, S. von Haehling, H. Bechtold, S. Genth Tags: Research Article Source Type: research

Biomarker Guidance allows a more personalized allocation of patients for Remote Patient Management in Heart Failure Results from the TIM ‐HF2 Trial
AbstractBackgroundThe TIM ‐HF2 study showed less days lost to unplanned cardiovascular hospitalization or all‐cause death and improved survival in patients randomly assigned to remote patient management (RPM) instead of standard of care (SOC).MethodsThis sub ‐study explored whether biomarkers MR‐proADM and NT‐proBNP could be used to identify low‐risk patients unlikely to benefit from RPM, thereby allowing more efficient allocation of the intervention. For N=1538 patients of the trial (median 73 years, IQR 64‐78 years, 30% female), baseline bio markers were used to select subpopulations recommended for RPM wit...
Source: European Journal of Heart Failure - May 25, 2019 Category: Cardiology Authors: Martin M öckel, Kerstin Koehler, Stefan D. Anker, Jörn Vollert, Volker Moeller, Magdalena Koehler, Stefan Gehrig, Jan C. Wiemer, Stephan von Haehling, Friedrich Koehler Tags: Research Article Source Type: research